UK private equity group buys Doppel Farmaceutici citing EU CDMO market potential

By Gareth Macdonald

- Last updated on GMT

Doppel Farmaceutici manufacturing site in Cortemaggiore
Doppel Farmaceutici manufacturing site in Cortemaggiore

Related tags Private equity Supply chain management Private equity firm

Trilantic Capital Partners Europe has bought a majority stake in Doppel Farmaceutici, citing the growth potential of Europe’s contracting market as the driver.

Doppel Farmaceutici, headquartered just outside Piacenza in Northern Italy, provides contract development and manufacturing services for the pharmaceutical industry, including formulation development and packaging.

UK-based private equity firm Trilantic bought a 90% stake in Doppel from previous shareholders, including long-time backer Pierluigi Busca and founder Paolo Lanfranchi. The latter will retain a 10% holding in the firm.

In an official statement Trilantic said the “the CDMO pharmaceutical sector is expected to grow significantly in the next five years.​”

A spokewman for the private equity firm told us: "We believe Doppel is a solid platform that is competitive in the market thanks to its good R&D department and broad customer base. We think this, plus a solid good reputation and well invested manufacturing plants are key elements that allow Doppel to compete in the market.​"

He added that growth of Europe's contracting sector will be driven by the "emergence of new sets of players like start-ups and generic marketers applying a virtual supply chain model having no own manufacturing activities.

"The cost dimension is becoming increasingly important in the pharmaceutical industry given mounting pressures on unit prices​" he added.

The spokesman also suggested that: "Manufacturing and supply chain management related activities more and more viewed by pharmaceutical companies and their financial stakeholders as contributing little to value creation and as non-core​."

This creates demand for efficient contractors that are able to clear the "escalating regulatory hurdles​" from pharmaceutical firms which "realize that major inefficiencies often plague their own operations detrimentally impacting their cost structure​."

Doppel employs a staff of 460 people and operates two manufacturing sites in Cortemaggiore and Rozzano in Northern Italy.

According to a statement the privately-owned contractor generated revenue of  €83.4m ($73.8m) and EBITDA of €12.3m, with 63% of its business coming from the domestic market.

Doppel is also involved in contract manufacturing for the medical device, cosmetics, food and nutritional supplements sectors through Procemsa Farmaceutici, in which it holds a 24.7% stake.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more